Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Bernstein launched its coverage of Biogen (NASDAQ:BIIB) on Tuesday with a Market Perform recommendation ahead of its Q4 earnings release this week, citing a difficult sales trajectory for the ...

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...

Biogen Inc. (NASDAQ:BIIB)’s commercial strategies are expected to enhance the uptake of Leqembi. Furthermore, the company continues to focus on its pipeline, with expected regulatory filings ...